160 completed, 55 terminated, 31 unknown, 12 recruiting. 275 Phase 2, 31 Phase 1, 3 Phase 3.
Follow Sunitinib: new trials by email Literature Review of Sunitinib trials Research Report on Sunitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma Methotrexate, Doxorubicin, Cisplatin - Osteosarcoma, Metastasis | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-03-11 | 2026-03-17 |
| Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment [177Lu]Lu-DOTATATE, Standard of Care treatments - Intracranial Meningioma | Phase 2 | Recruiting | RTOG Foundation, Inc. | 130 | 2025-08-24 | 2026-10-02 |
| 177Lu-DOTATATE for Recurrent Meningioma Local standard of Care, 177Lu-DOTATATE - Recurrent Meningioma | Phase 2 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 136 | 2025-03-10 | 2026-06-15 |
| Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC Bicalutamide in combination with Sunitinib - Carcinoma, Renal Cell | Phase 1 / Phase 2 | Recruiting | State University of New York at Buffalo | 28 | 2024-10-01 | 2026-04-01 |
| SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST Bezuclastinib in combination with sunitinib - Gastrointestinal Stromal Tumors, GIST | Phase 2 | Active not recruiting | Sarcoma Alliance for Research through Collaboration | 40 | 2024-08-01 | 2025-10-31 |
| Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial Biospecimen Collection, Cabozantinib, Computed Tomography - Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 100 | 2024-01-12 | 2026-10-28 |
| ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST Sunitinib, Regorafenib - Gastrointestinal Stromal Tumors | Phase 2 | Recruiting | University of Miami | 48 | 2023-10-17 | 2026-10-23 |
| Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors Lenvatinib + Envafolimab, Sunitinib - Solid Tumors, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | 3D Medicines (Sichuan) Co., Ltd. | 170 | 2021-11-15 | 2026-03-25 |
| Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors Palbociclib, Sunitinib - Solid Tumors Refractory to Standard Therapy | Phase 1 / Phase 2 | Recruiting | Rabin Medical Center | 100 | 2021-10-21 | 2025-04-23 |
| A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib Ripretinib, Sunitinib - Gastrointestinal Stromal Tumor(GIST) | Phase 2 | Completed | Zai Lab (Shanghai) Co., Ltd. | 108 | 2020-11-25 | 2026-04-03 |
| Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC) Sunitinib Malate, TAS 102 - Colorectal Cancer, Metastasis | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 60 | 2019-10-01 | 2020-11-13 |
| A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Drug: GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 2 | Completed | Graybug Vision | 56 | 2019-09-26 | 2022-01-19 |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion GB-102 - Diabetic Macular Edema, Retina Vein Occlusion | Phase 2 | Completed | Graybug Vision | 21 | 2019-09-11 | 2021-11-22 |
| Pan Tumor Rollover Study Nivolumab, Ipilimumab, Cabozantinib - Cancer | Phase 2 | Recruiting | Bristol-Myers Squibb | 1500 | 2019-08-09 | 2026-10-30 |
| Sunitinib in Sarcomas of the Central Nervous System Sunitinib, wGT3x-BT - Gliosarcoma, Central Nervous System Sarcoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-02-21 | 2022-04-19 |
| Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma Propranolol, Sunitinib - Renal Cell Carcinoma | Phase 2 | Withdrawn | Military Institute od Medicine National Research Institute | 2018-09-01 | 2019-01-09 | |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Sunitinib, Lomustine - Glioblastoma Multiforme, Glioblastoma, Adult | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 100 | 2018-08-31 | 2021-04-19 |
| Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Laboratory Biomarker Analysis, Pembrolizumab, Sunitinib Malate - Thymic Carcinoma | Phase 2 | Active not recruiting | Dwight Owen | 9 | 2018-06-19 | 2026-08-06 |
| Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma Cabozantinib, Sunitinib Malate - Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2018-05-15 | 2026-07-16 |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) Olaparib, Dasatinib, Nivolumab plus Ipilimumab - Lymphoma, Non-Hodgkin, Multiple Myeloma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 720 | 2018-03-23 | 2026-03-27 |
Showing 20 of 275. Sign in to see all of them.
Carcinoma, Renal Cell (74) · Neoplasm Metastasis (27) · Kidney Neoplasms (22) · Breast Neoplasms (20) · Neoplasms (17) · Carcinoma, Non-Small-Cell Lung (14) · Urinary Bladder Neoplasms (13) · Prostatic Neoplasms (12) · Brain Neoplasms (9) · Colorectal Neoplasms (9) · Melanoma (9) · Carcinoma, Hepatocellular (8) · Gastrointestinal Stromal Tumors (8) · Lung Neoplasms (8) · Glioblastoma (7)
National Cancer Institute (NCI) (31) · Pfizer (28) · M.D. Anderson Cancer Center (9) · Memorial Sloan Kettering Cancer Center (8) · Case Comprehensive Cancer Center (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · Massachusetts General Hospital (5) · Central European Society for Anticancer Drug Research (4) · Duke University (4) · National University Hospital, Singapore (4) · University Health Network, Toronto (4) · Amsterdam UMC, location VUmc (3) · Assistance Publique - Hôpitaux de Paris (3) · Dana-Farber Cancer Institute (3) · Genentech, Inc. (3)
United States (146) · France (35) · Canada (30) · Germany (23) · Spain (20) · Italy (19) · South Korea (15) · United Kingdom (13) · Netherlands (12) · China (10) · Taiwan (9) · Japan (8) · Poland (7) · Austria (6) · Belgium (6)
Eric Jonasch, MD (3) · Robert J. Motzer, MD (3) · Amado Zurita, MD (2) · Andrew X. Zhu, MD (2) · Arun Rajan, M.D. (2) · Dean F. Bajorin, MD (2) · Enrique Grande, MD (2) · Guru Sonpavde, MD (2) · Hope S. Rugo, MD (2) · Jonathan Strosberg, MD (2) · M. Dror Michaelson, MD, PhD (2) · Markus Moehler, MD (2)
PMID 37146227, PMID 25577718, PMID 27238653, PMID 28410911, PMID 23228446, PMID 33852135, PMID 12712448, PMID 15201427, PMID 15725919, PMID 16757724, PMID 17570676, PMID 19403935, PMID 19451429, PMID 19461405, PMID 19536893, PMID 19547919, PMID 19586800, PMID 19652072, PMID 20142724, PMID 20189981, PMID 20203173, PMID 20652398, PMID 20711632, PMID 20975250, PMID 21148613, PMID 21174224, PMID 21277078, PMID 21512407, PMID 21531821, PMID 21664867, PMID 21787417, PMID 21898376, PMID 22045104, PMID 22105611, PMID 22176869, PMID 22228449, PMID 22261812, PMID 22377563, PMID 22425095, PMID 22537162, PMID 22614181, PMID 22761653, PMID 22837187, PMID 22897944, PMID 22984218, PMID 23182663, PMID 23228299, PMID 23269537, PMID 23625328, PMID 23660867
2008 (4), P30CA008748 (4), U10CA031946 (4), 2014 (3), 2016 (3), N01CM62201 (3), N01CM62203 (3), P30CA043703 (3), U10CA180821 (3), 2009 (2), 2015 (2), N01CM62202 (2), P30CA014599 (2), U10CA027469 (2), U10CA180820 (2)